Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire establishes U.S. headquarters

Executive Summary

U.K.-based Shire sets up North American headquarters in Wayne, Penn. and plans to close its facilities in Rockville, Md. and Newport, Ky. The new facility will house about 400 employees by end of 2005. Establishing a U.S. headquarters was one step in a streamlining effort announced by CEO Matthew Emmens shortly after he joined the company this spring (1"The Pink Sheet" March 17, 2004, In Brief)...

You may also be interested in...

Shire hires ex-Merck exec

Former Merck KGaA global ethical pharmaceuticals president Matthew Emmens named CEO of Shire effective March 19. Emmens succeeds Rolf Stahel, who announced his intention to leave the company in October. Emmens previously spent 19 years at U.S. Merck & Co., and was CEO of Astra Merck joint venture...

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients

As China Rushes Medical Supplies To World, Quality Issues Resurface

As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts